TMO Thermo Fisher Scientific (TMO) Insider Trading, Ownership & Congress Trades
Industrials · Measuring & controlling devices, nec · CIK 0000097745
Congress · 1Form 144 · 11
Insider buyers, 180 days
0
Funds added, last quarter
1,143
13F, latest reported quarter
Conversions, 180 days
12
Codes C/M, not in net · $29.9M priced
What the filings say about TMO
Insiders, 180 days
-$61.6M net sold
5 sellers · 22% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 3 sold
Latest: sale, 2026-07-10
Planned sales (Form 144), 90 days
$61.2M
11 notices
Thermo Fisher Scientific insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, THERMO FISHER SCIENTIFIC INC. insiders sold a net $61.6M of stock across 904 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jul 27, 2026.
- The trade is 1.7% of the 23,216 shares held after it.
- 4 other insiders sold within 30 days.
- 1,143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & COO Pettiti Gianluca sold about $245.8K of TMO under a 10b5-1 plan on Aug 31, 2026; 4 other insiders sold within 30 days and 1,143 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jul 27, 2026.
- The trade is 16.1% of the 23,216 shares held after it.
- 4 other insiders sold within 30 days.
- 1,143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & COO Pettiti Gianluca sold about $2.3M of TMO under a 10b5-1 plan on Aug 31, 2026; 4 other insiders sold within 30 days and 1,143 funds added in the latest 13F quarter.Context
- 747 earlier Form 4 trades (code P or S) here by this insider (747 sales), the last on Aug 21, 2026.
- The trade is 0.1% of the 124,099 shares held after it.
- 4 other insiders sold within 30 days.
- 1,143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO CASPER MARC N sold about $63.2K of TMO under a 10b5-1 plan on Aug 24, 2026; 4 other insiders sold within 30 days and 1,143 funds added in the latest 13F quarter.Context
- 747 earlier Form 4 trades (code P or S) here by this insider (747 sales), the last on Aug 21, 2026.
- The trade is 0.0% of the 124,066 shares held after it.
- 4 other insiders sold within 30 days.
- 1,143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO CASPER MARC N sold about $20.7K of TMO under a 10b5-1 plan on Aug 24, 2026; 4 other insiders sold within 30 days and 1,143 funds added in the latest 13F quarter.Context
- 747 earlier Form 4 trades (code P or S) here by this insider (747 sales), the last on Aug 21, 2026.
- The trade is 0.1% of the 123,987 shares held after it.
- 4 other insiders sold within 30 days.
- 1,143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO CASPER MARC N sold about $49.6K of TMO under a 10b5-1 plan on Aug 24, 2026; 4 other insiders sold within 30 days and 1,143 funds added in the latest 13F quarter.904 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$61.6M over 180 days
-$61.3M over 90 days
below 94% of Industrials
Congress
1 member bought in the last year
the lowest in Industrials
Funds
1,143 funds bought in last quarter
more than 98% of Industrials
Revenue
+3.9% year over year
below 54% of Industrials
Margin
15.0% net margin
more than 88% of Industrials
Buybacks
$4.0B repurchased, FY to 2026-06-27
more than 99% of Industrials
Short interest
1.5% of the float short (float per yahoo 2026-10-26) · 2.1 days to cover · settled 2026-09-30
below 75% of Industrials
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TMO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+21.1%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TMO: institutional holders (13F)
13F holdings, latest reported quarter
30,919,632 sh
$15.5B
24,276,316 sh
$12.2B
16,825,879 sh
$8.4B
14,084,488 sh
$7.1B
10,763,066 sh
$5.4B
Congress trades in TMO
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-07-10 · disclosed 7 days later
$1,001 - $15,000
Sold 2026-05-07 · disclosed 8 days later
$1,001 - $15,000
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TMO planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Pettiti Gianluca
Filed 2026-08-31
$2.5M
CASPER MARC N
Filed 2026-08-24
$172.4K
CASPER MARC N
Filed 2026-08-21
$6.3M
CASPER MARC N
Filed 2026-08-20
$6.3M
Britt Lisa P.
Filed 2026-08-19
$7.0M
TMO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Medical Technology and Devices Portfolio
$418.6M position · as of 2026-05-31
14.1%
Eaton Vance Atlanta Capital Focused Growth Fund
$40.3M position · as of 2026-06-30
8.6%
Fidelity Advisor Health Care Fund
$196.7M position · as of 2026-07-31
6.3%
Weitz Large Cap Equity Fund
$36.6M position · as of 2026-06-30
5.9%
VIP Health Care Portfolio
$58.2M position · as of 2026-06-30
5.0%
Weitz Partners III Opportunity Fund
$16.0M position · as of 2026-06-30
4.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Commerce
SUITE OF SCANNING TRANSMISSION ELECTRON MICROSCOPE (STEM) AND TRANSMISSION ELECTRON MICROSCOPE (TEM) · 2023-12-22
$9.9M
Department Of Commerce
FOCUSED ION BEAM SCANNING ELECTRON MICROSCOPES · 2023-09-15
$6.7M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Mr. Casper
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$79.9M
$116.1M
$7.6M
+26%
+57%
2024
$30.4M
$29.6M
$10.9M
+13%
+35%
2023
$19.0M
$9.2M
$5.5M
+15%
+28%
2022
$28.2M
-$4.7M
$5.9M
+19%
+22%
2021
$21.2M
$65.9M
$8.2M
+44%
+25%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $61.6M sold by insiders over 180 days, 1,143 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $61.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
TMO financials
Revenue growth
+3.9%
XBRL, annual
Net margin
15.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$46.3B
four quarters, 2025-06-29 to 2026-06-27
Revenue, TTM TMO
| FY Dec 2025 | $44.6B |
| FY Dec 2024 | $42.9B |
| FY Dec 2023 | $42.9B |
| FY Dec 2022 | $44.9B |
| FY Dec 2021 | $39.2B |
| Jun 2026 | $12.0B |
| Mar 2026 | $11.0B |
| Dec 2025 | $12.2B |
| Sep 2025 | $11.1B |
| Jun 2025 | $10.9B |
| Mar 2025 | $10.4B |
| Dec 2024 | $11.4B |
| Sep 2024 | $10.6B |
At each fiscal year end
Single quarter
Net margin, TTM
+15.1%
net income over revenue, 2025-06-29 to 2026-06-27
Net margin, TTM TMO
| FY Dec 2025 | +15.1% |
| FY Dec 2024 | +14.8% |
| FY Dec 2023 | +13.9% |
| FY Dec 2022 | +15.5% |
| FY Dec 2021 | +19.7% |
| Jun 2026 | +14.5% |
| Mar 2026 | +15.0% |
| Dec 2025 | +16.2% |
| Sep 2025 | +14.5% |
| Jun 2025 | +14.9% |
| Mar 2025 | +14.5% |
| Dec 2024 | +16.1% |
| Sep 2024 | +15.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$7.3B
operating cash flow minus capex, 2025-06-29 to 2026-06-27
Free cash flow, TTM TMO
| FY Dec 2025 | $6.3B |
| FY Dec 2024 | $7.3B |
| FY Dec 2023 | $6.9B |
| FY Dec 2022 | $6.9B |
| FY Dec 2021 | $6.8B |
| Jun 2026 | $1.7B |
| Mar 2026 | $816.0M |
| Dec 2025 | $3.0B |
| Sep 2025 | $1.8B |
| Jun 2025 | $1.1B |
| Mar 2025 | $361.0M |
| Dec 2024 | $2.8B |
| Sep 2024 | $1.9B |
At each fiscal year end
Single quarter
Debt to equity
0.87x
long-term 2026-06-27 plus current 2026-06-27; equity 2026-06-27
Debt to equity TMO
| FY Dec 2025 | 0.80x |
| FY Dec 2024 | 0.67x |
| FY Dec 2023 | 0.82x |
| FY Dec 2022 | 0.91x |
| FY Dec 2021 | 0.91x |
| Jun 2026 | 0.87x |
| Mar 2026 | 0.89x |
| Dec 2025 | 0.80x |
| Sep 2025 | 0.77x |
| Jun 2025 | 0.74x |
| Mar 2025 | 0.75x |
| Dec 2024 | 0.67x |
| Sep 2024 | 0.80x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.20x
TTM operating cash flow over long-term 2026-06-27 plus current 2026-06-27
Cash flow to debt TMO
| FY Dec 2025 | 0.18x |
| FY Dec 2024 | 0.26x |
| FY Dec 2023 | 0.22x |
| FY Dec 2022 | 0.23x |
| FY Dec 2021 | 0.25x |
| Jun 2026 | 0.20x |
| Mar 2026 | 0.18x |
| Dec 2025 | 0.18x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.20x |
| Mar 2025 | 0.22x |
| Dec 2024 | 0.26x |
| Sep 2024 | 0.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+13.5%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on equity TMO
| FY Dec 2025 | +13.1% |
| FY Dec 2024 | +13.2% |
| FY Dec 2023 | +13.1% |
| FY Dec 2022 | +16.4% |
| FY Dec 2021 | +20.5% |
| Jun 2026 | +13.5% |
| Mar 2026 | +13.6% |
| Dec 2025 | +13.1% |
| Sep 2025 | +13.1% |
| Jun 2025 | +13.5% |
| Mar 2025 | +13.7% |
| Dec 2024 | +13.2% |
| Sep 2024 | +13.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.5%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on assets TMO
| FY Dec 2025 | +6.5% |
| FY Dec 2024 | +6.5% |
| FY Dec 2023 | +6.1% |
| FY Dec 2022 | +7.2% |
| FY Dec 2021 | +9.4% |
| Jun 2026 | +6.5% |
| Mar 2026 | +6.5% |
| Dec 2025 | +6.5% |
| Sep 2025 | +6.5% |
| Jun 2025 | +6.6% |
| Mar 2025 | +6.6% |
| Dec 2024 | +6.5% |
| Sep 2024 | +6.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+8.1%
operating income after a 7.8% effective tax rate, over long-term 2026-06-27 plus current 2026-06-27 plus average of 2025-06-28 and 2026-06-27 minus cash
Return on invested capital TMO
| FY Dec 2025 | +8.2% |
| FY Dec 2024 | +8.8% |
| FY Dec 2023 | +8.7% |
| FY Dec 2022 | +10.1% |
| FY Dec 2021 | +13.0% |
| Jun 2026 | +8.1% |
| Mar 2026 | +7.9% |
| Dec 2025 | +8.2% |
| Sep 2025 | +8.1% |
| Jun 2025 | +8.6% |
| Mar 2025 | +8.7% |
| Dec 2024 | +8.8% |
| Sep 2024 | +8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+8.7%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-06-27 minus current liabilities
Return on capital employed TMO
| FY Dec 2025 | +8.6% |
| FY Dec 2024 | +8.7% |
| FY Dec 2023 | +8.3% |
| FY Dec 2022 | +10.4% |
| FY Dec 2021 | +14.3% |
| Jun 2026 | +8.7% |
| Mar 2026 | +8.6% |
| Dec 2025 | +8.6% |
| Sep 2025 | +8.6% |
| Jun 2025 | +8.6% |
| Mar 2025 | +8.7% |
| Dec 2024 | +8.7% |
| Sep 2024 | +8.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
36.84x
close 2026-10-26 over four quarters of diluted EPS, 2025-06-29 to 2026-06-27
P/E, trailing TMO
| FY Dec 2025 | 32.66x |
| FY Dec 2024 | 31.47x |
| FY Dec 2023 | 34.36x |
| FY Dec 2022 | 31.24x |
| FY Dec 2021 | 34.31x |
| Jun 2026 | 27.60x |
| Mar 2026 | 26.02x |
| Dec 2025 | 32.66x |
| Sep 2025 | 26.82x |
| Jun 2025 | 23.61x |
| Mar 2025 | 29.33x |
| Dec 2024 | 31.47x |
| Sep 2024 | 38.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$294.8B
market value at close 2026-10-26 on 2026-06-27 shares, plus long-term 2026-06-27 plus current 2026-06-27, minus cash 2026-06-27
Enterprise value TMO
| FY Dec 2025 | $250.6B |
| FY Dec 2024 | $228.3B |
| FY Dec 2023 | $235.3B |
| FY Dec 2022 | $247.3B |
| FY Dec 2021 | $295.7B |
| Jun 2026 | $231.3B |
| Mar 2026 | $218.7B |
| Dec 2025 | $250.6B |
| Sep 2025 | $211.7B |
| Jun 2025 | $186.8B |
| Mar 2025 | $221.5B |
| Dec 2024 | $228.3B |
| Sep 2024 | $269.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield TMO
| FY Dec 2025 | +2.9% |
| FY Dec 2024 | +3.7% |
| FY Dec 2023 | +3.4% |
| FY Dec 2022 | +3.2% |
| FY Dec 2021 | +2.6% |
| Jun 2026 | +3.9% |
| Mar 2026 | +3.8% |
| Dec 2025 | +2.9% |
| Sep 2025 | +3.5% |
| Jun 2025 | +4.0% |
| Mar 2025 | +3.6% |
| Dec 2024 | +3.7% |
| Sep 2024 | +3.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
4.90x
P/E over trailing EPS growth of 8%: four quarters to 2026-06-27 against the four to 2025-06-28
PEG, trailing TMO
| FY Dec 2025 | 4.46x |
| FY Dec 2024 | 4.50x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.57x |
| Jun 2026 | 3.67x |
| Mar 2026 | 3.89x |
| Dec 2025 | 4.46x |
| Sep 2025 | 3.15x |
| Jun 2025 | 3.25x |
| Mar 2025 | 3.13x |
| Dec 2024 | 4.50x |
| Sep 2024 | 8.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $44.6B | $42.9B | $42.9B | $44.9B |
| Operating income | $7.7B | $7.3B | $6.9B | $8.4B |
| Net income | $6.7B | $6.3B | $6.0B | $7.0B |
| EPS (diluted) | 17.74 | 16.53 | 15.45 | 17.63 |
| Operating cash flow | $7.8B | $8.7B | $8.4B | $9.2B |
| Cash | $9.9B | $4.0B | $8.1B | $8.5B |
| Long-term debt | $39.2B | $31.1B | $34.7B | $34.3B |
| Buybacks | $3.0B | $4.0B | $3.0B | $3.0B |
| Dividends paid | $636.0M | $583.0M | $523.0M | $455.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
TMO Stock Sonar score 6/7 axes
Find similar shapesCompareTMO ranks highest on risk and compliance (83rd percentile) and institutional and government (63rd), and lowest on insider conviction (3rd), among Industrials peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TMO filings, in plain words
Are Thermo Fisher Scientific insiders buying or selling TMO?
In the 180 days to 2026-10-27, Thermo Fisher Scientific insiders were net sellers, a net $61.6M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded TMO?
Yes. In the year to 2026-10-27, 1 House member disclosed buying TMO and 3 House members disclosed selling it; the latest on record is a sale by Dan Newhouse dated 2026-07-10.
Are there planned insider sales of TMO?
Yes. 11 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $61.2M of stock; the latest, by Pettiti Gianluca, was filed 2026-08-31.
Read the full summary
In the 180 days to 2026-10-27, Thermo Fisher Scientific insiders were net sellers of TMO, a net $61.6M across purchases and sales reported on Form 4 by 5 sellers. 22% of the 93 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying TMO and 3 members disclosed selling it; the latest on record is a sale by Dan Newhouse dated 2026-07-10. Insiders filed 11 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $61.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
